Theramir Ltd is pleased to have successful completed the kick-off meeting for its groundbreaking project EXCELL which was on January 17, 2025, at Theramir's headquarters in the ASBIS High Tech Cluster conference facilities.

The EXCELL project, supported by the European Union Recovery and Resilience Facility of the NextGenerationEU instrument through the Research and Innovation Foundation (IDEK), has received funding of €150,000 under the Call “POST-DOC/0524/0155”.

EXCELL aims to combine the expertise of each member of the Theramir team to explore the mode of action of EVmiR, Theramir’s patented technology, and its potential as treatment of bladder cancer. EVmiR is engineered to target aggressive, treatment-resistant and metastatic cancer - a group that encompasses more than 30 types of malignancies. This platform harnesses extracellular vesicles (EVs) to deliver microRNAs (miRNAs) directly into tumors, where they target oncogenic proteins that fuel cancer cell proliferation.

The kick-off meeting served as the strategic platform for in-depth discussion and planning, outlining the project’s objective and milestones. The meeting involved a comprehensive presentation from Dr Marina Hadjicharalambous-Ryder, the project coordinator, which highlighted key goals and milestones of the project as well as the next steps ahead.

Dr. Marina Hadjicharalambous-Ryder, the scientific coordinator of the project along with Theramir’s team will drive the project and ensure its timely execution. Theramir’s scientific consortium consist of Dr Marianna Prokopi-Demetriades, co-founder and Director of Theramir and Theramir’s scientific team: Anna Katsioloudi, Dr Nikoletta Christodoulou and Giannis Andronikou.

Theramir Ltd expresses its commitment to advancing the field of cancer therapeutics as well as to achieving the project’s objectives and looks forward to the impactful outcomes that will emerge from the “EXCELL” project.